Mouse tumor susceptibility genes identify drug combinations for multiple myeloma

Abstract

Long-term genetic studies utilizing backcross and congenic strain analyses coupled with positional cloning strategies and functional studies identified Cdkn2a, Mtor, and Mndal as mouse plasmacytoma susceptibility/resistance genes. Tumor incidence data in congenic strains carrying the resistance alleles of Cdkn2a and Mtor led us to hypothesize that drug combinations affecting these pathways are likely to have an additive, if not synergistic effect in inhibiting tumor cell growth. Traditional and novel systems-level genomic approaches were used to assess combination activity, disease specificity, and clinical potential of a drug combination involving rapamycin/everolimus, an Mtor inhibitor, with entinostat, an histone deacetylase inhibitor. The combination synergistically repressed oncogenic MYC and activated the Cdkn2a tumor suppressor. The identification of MYC as a primary upstream regulator led to the identification of small molecule binders of the G-quadruplex structure that forms in the NHEIII region of the MYC promoter. These studies highlight the importance of identifying drug combinations which simultaneously upregulate tumor suppressors and downregulate oncogenes.

Keywords

Complex genetic trait / plasma cell tumor / multiple myeloma / entinostat / rapamycin / drug combinations / Cdkn2a / Mtor / Mndal / MYC

References

[1] Martincorena I.Somatic mutation in cancer and normal cells..Science2015;349:1483-9

[2] Park S,Lehner B.Systematic discovery of germline cancer predisposition genes through the identification of somatic second hits..Nat Commun2018;9:2601 PMCID:PMC6031629

[3] Sud A,Houlston RS.Genome-wide association studies of cancer: current insights and future perspectives..Nat Rev Cancer2017;17:692-704

[4] Mock BA,Dosik JK.Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis..Proc Natl Acad Sci USA1993;90:9499-503 PMCID:PMC47596

[5] Mock BA,Le Tissier P,Potter M.The plasmacytoma resistance gene, Pctr2, delays the onset of tumorigenesis and resides in the telomeric region of chromosome 4..Blood1997;90:4092-8

[6] Zhang S,Mock BA.Cdkn2a, the cyclin dependent kinase inhibitor encoding p16^INK4a and p19^ARF is a candidate for the plasmacytoma susceptibility locus, Pctr1..Proc Natl Acad Sci USA1998;95:2429-34 PMCID:PMC19364

[7] Zhang S.The role of p16^INK4a (Cdkn2a) in mouse plasma cell tumors..Curr Top Microbiol Immunol1999;246:363-7

[8] Potter M,Wax JS,Mock BA.Identification of two genes on chromosome 4 determine resistance to plasmacytoma induction in mice..Cancer Res1994;54:969-75

[9] Mock BA,Ramsay ES,Zhang K.Strategies for dissecting complex traits associated with cancer: lessons from plasma cell tumors..AACR Education Book2005;2005:273-6

[10] Krall M,Zimmerman K,Dosik J.Isolation and mapping of four new DNA markers from mouse chromosome 4..Mamm Genome1992;3:653-5

[11] Bliskovsky V,Scott J,Shi W.Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene..Proc Natl Acad Sci USA2003;100:14982-7 PMCID:PMC299869

[12] Zhang K,DuBois W,Bliskovsky V.Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility..Blood2009;114:2952-60 PMCID:PMC2756205

[13] Janz S.Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice..J Natl Cancer Inst Monogr2008;37-40

[14] Dib A,Glebov OK,Kuehl WM.Characterization of MYC translocations in multiple myeloma cell lines..J Natl Cancer Inst Monogr2008;25-31 PMCID:PMC2737184

[15] Zhang SL,Ramsay ES,Morse HC3rd.Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility..Mol Cell Biol2001;21:310-8 PMCID:PMC88804

[16] Zhang S,Redman C,Ramsay ES.p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB..Oncogene2003;22:2285-95

[17] Zhang S,Ramsay ES,Eiden AM.The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility..J Biol Chem2019;294:16756-64 PMCID:PMC6851318

[18] Boyle EM,Leleu X.Understanding the multiple biological aspects leading to myeloma..Haematologica2014;99:605-12 PMCID:PMC3971069

[19] Simmons JK,Gamache BJ,Patel J.Cooperative targets of combined mTOR/HDAC inhibition promote MYC degradation..Mol Cancer Ther2017;16:2008-21 PMCID:PMC5587368

[20] Simmons JK,Michalowski A,Wei BR.TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms..Mol Oncol2014;8:261-72 PMCID:PMC3969848

[21] Zhan F,Colla S,Hanamura I.The molecular classification of multiple myeloma..Blood2006;108:2020-8 PMCID:PMC1895543

[22] Chng WJ,Vanwier S,Price-Troska T.Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling..Cancer Res2007;67:2982-9

[23] Tiedemann RE,Schmidt J,Shi CX.Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6..Blood2010;115:1594-604 PMCID:PMC2830764

[24] Chng WJ,Chung TH,Keats JJ.Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma..Leukemia2010;24:833-42 PMCID:PMC2977975

[25] Chng WJ,Chung TH,Gonzalez-Paz N.Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma..Leukemia2011;25:1026-35 PMCID:PMC3432644

[26] Felsenstein KM,Simmons JK,Calabrese DR.Small molecule microarrays enable the identification of a selective, quadruplex-binding inhibitor of MYC expression..ACS Chem Biol2016;11:139-48 PMCID:PMC4719142

[27] Calabrese DR,Leon EC,Phyo Z.Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex..Nat Commun2018;9:4229 PMCID:PMC6185959

[28] Grandori C.Personalized cancer models for target discovery and precision Medicine..Trends Cancer2018;4:634-42 PMCID:PMC6242713

[29] Mock B,Clynes R,Potter M.The genetics of susceptibility to RIM-induced plasmacytomagenesis..Curr Top Microbiol Immunol1988;141:125-7

[30] Misund K,Stein CK,Day G.MYC dysregulation in the progression of multiple myeloma..Leukemia2020;34:322-6 PMCID:PMC6923575

[31] Kadoch C,Keilhack H.PRC2 and SWI/SNF chromatin remodeling complexes in health and disease..Biochemistry2016;55:1600-14

[32] Orlando KA,Raab JR,Weissman BE.Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities..Expert Rev Anticancer Ther2019;19:375-91 PMCID:PMC6533634

[33] Lander ES,Birren B,Zody MC.Initial sequencing and analysis of the human genome..Nature2001;409:860-921

[34] Venter JC,Myers EW,Mural RJ.The sequence of the human genome..Science2001;291:1304-51

[35] Chapman MA,Keats JJ,Sougnez C.Initial genome sequencing and analysis of multiple myeloma..Nature2011;471:467-72 PMCID:PMC3560292

[36] Schürch CM,Frauenfeld L,Fend F.A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration..Virchows Arch2020;476:337-51

[37] Rustad EH,Leongamornlert D,Ledergor G.Timing the initiation of multiple myeloma..Nat Commun2020;11:1917 PMCID:PMC7174344

[38] Maura F,Boyle EM.Reconstructing the evolutionary history of multiple myeloma..Best Pract Res Clin Haematol2020;33:101145

[39] Rasche L,Raab MS.The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma..Int J Mol Sci2019;20:1248 PMCID:PMC6429294

[40] Merz M,Hielscher T,Schönland SO.Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma..Blood Adv2017;2:1-9 PMCID:PMC5761630

[41] Ledergor G,Zada M,Cohen YC.Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma..Nat Med2018;24:1867-76

[42] Maura F,Angelopoulos N,Leongamornlert D.Genomic landscape and chronological reconstruction of driver events in multiple myeloma..Nat Commun2019;10:3835 PMCID:PMC6707220

[43] Lonial S,Liang W,Aldrich J.Interim analysis of the mmrf commpass trial: identification of novel rearrangements potentially associated with disease initiation and progression..Blood2014;124:722

[44] Kuehl WM.Multiple myeloma: evolving genetic events and host interactions..Nat Rev Cancer2002;2:175-87

[45] Stewart AK,Greipp PR,Gertz MA.A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy..Leukemia2007;21:529-34

[46] Chesi M,Sebag M,Affer M.AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies..Cancer Cell2008;13:167-80 PMCID:PMC2255064

[47] Cheung WC,Linden M,Van Ness B.Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice..J Clin Invest2004;113:1763-73 PMCID:PMC420503

[48] Radl J,Zurcher C,de Leeuw AM.Animal model of human disease. Multiple myeloma..Am J Pathol1988;132:593-7 PMCID:PMC1880745

[49] Tompkins VS,Holman CJ,Olivier AK.Adoptive B-cell transfer mouse model of human myeloma..Leukemia2016;30:962-6 PMCID:PMC4821809

[50] Vlummens P,Menu E,Offner F.The use of murine models for studying mechanistic insights of genomic instability in multiple myeloma..Front Genet2019;10:740 PMCID:PMC6704229

[51] Rajagopalan A,Furumo Q,Finn R.Mice expressing MYC and NrasQ61R in germinal venter B vells fevelop highly aggressive multiple myeloma..Blood2018;132:1006

[52] Mitchell JS,Weinhold N,Ali M.Genome-wide association study identifies multiple susceptibility loci for multiple myeloma..Nat Commun2016;7:12050 PMCID:PMC4932178

[53] Morgan GJ,Weinhold N,Landgren O.Inherited genetic susceptibility to multiple myeloma..Leukemia2014;28:518-24

[54] Swaminathan B,Jöud M,Johnsson E.Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma..Nat Commun2015;6:7213 PMCID:PMC4455110

[55] Chubb D,Broderick P,Johnson DC.Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk..Nat Genet2013;45:1221-5 PMCID:PMC5053356

[56] Weinhold N,Chubb D,Försti A.The CCND1.c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma..Nat Genet2013;45:522-5 PMCID:PMC5056630

[57] Broderick P,Johnson DC,Försti A.Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk..Nat Genet2011;44:58-61 PMCID:PMC5108406

[58] Chattopadhyay S,Yadav P,Weinhold N.Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma..Commun Biol2019;2:89 PMCID:PMC6399257

[59] Walker BA,Brioli A,Kaiser MF.Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients..Blood Cancer J2014;4:e191 PMCID:PMC3972699

[60] Li ZR,Qu C,Zhang MQ.A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma cells..Proc Natl Acad Sci USA2003;100:8164-9 PMCID:PMC166200

[61] Mathsyaraja H,Cheng PF,Catchpole JT.Max deletion destabilizes MYC protein and abrogates Emicro-Myc lymphomagenesis..Genes Dev2019;33:1252-64 PMCID:PMC6719623

[62] Filippakopoulos P,Picaud S,Smith WB.Selective inhibition of BET bromodomains..Nature2010;468:1067-73 PMCID:PMC3010259

[63] Balasubramanian S,Neidle S.Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?.Nat Rev Drug Discov2011;10:261-75 PMCID:PMC3119469

[64] Wang KB,Wu G,Cushman M.Indenoisoquinoline topoisomerase inhibitors strongly bind and stabilize the MYC promoter G-quadruplex and downregulate MYC..J Am Chem Soc2019;141:11059-70 PMCID:PMC7307421